From time to time we use our own capital to make strategic investments in companies that fall outside our managed funds’ scope of interest. These investments are targeted at situations where our team is well positioned to have an especially high impact – frequently because of our special expertise and almost always because of our network of relationships throughout the industry. When making these kinds of investments, we seek out opportunities where members of our team can be involved in the startup (or even pre-startup) phase of the portfolio company’s life.

News

September 24, 2015 – Intarcia Therapeutics Announces Acquisition of Phoundry Pharmaceuticals

 

August 18, 2015 – New Peptide Company Phoundry Closes First Seed Funding